Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

BACKGROUND: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia. METHODS: In this randomized, double-blind, parallel-controlled phase II study, patients whose fasting s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Honghu, Cui, Beibei, Chen, Yiyu, Chen, Lin, Wang, Zhihong, Zhang, Ning, Yang, Yanlan, Wang, Xiaodong, Xie, Xiangliang, Sun, Lingyun, Dang, Wantai, Wang, Xianyang, Li, Runzi, Zou, Jianjun, Zhao, Yi, Liu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808016/
https://www.ncbi.nlm.nih.gov/pubmed/35126684
http://dx.doi.org/10.1177/1759720X211067304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808016/
https://www.ncbi.nlm.nih.gov/pubmed/35126684
http://dx.doi.org/10.1177/1759720X211067304

Ejemplares similares